EXEL News Alert Exelixis Inc (EXEL) 1.29 12/25/2014 00:53:27

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Exelixis Inc (EXEL) 1.29 $EXEL

3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 88.76 (+3.23), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07), EXEL: 1.29 (-0.01)

The Most Disappointing Clinical Failures in 2014
Motley Fool Staff - Motley Fool - Sun Dec 21, 6:32PM CST
Since roughly 90% of all clinical trials end in a failure, it isn't too shocking that 2014 boasted its fair share of clinical trial disappointments. But while failure is common and expected in the industry, some defeats were more disappointing than...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), AZN: 70.44 (+0.26), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), EXEL: 1.29 (-0.01)

Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 17, 9:26AM CST
It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline updates.
CYCC: 0.69 (+0.01), CBST: 100.29 (-0.09), SPHS: 0.46 (+0.02), CCXI: 6.64 (-0.04), ALXN: 181.96 (+3.09), EXEL: 1.29 (-0.01)

Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:30PM CST
Roche's (RHHBY) subsidiary Genentech and Exelixis announced the submission of NDA for cobimetinib/Zelboraf combination for unresectable locally advanced or metastatic melanoma with a BRAF V600 mutation.
MRK: 57.46 (+0.25), GSK: 42.85 (+0.11), EXEL: 1.29 (-0.01)

Exelixis' Partners File New Drug Application For Cobemetinib - Welcome News But Little Impact
Christopher F. Davis - at Seeking Alpha - Tue Dec 16, 12:24AM CST

EXEL: 1.29 (-0.01)

3 Healthcare Stocks to Watch in 2015
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 15, 8:41AM CST
Source: Sanofi. The end of the year brings with it yuletide cheer, gatherings with friends and families, and perhaps even the swapping of holiday gifts. For healthcare investors, the end of the year also brings with it time to reflect on the year...
GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18), EXEL: 1.29 (-0.01)

Roche submits NDA for skin cancer med
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 6:14AM CST

EXEL: 1.29 (-0.01)

Exelixis' Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma
Business Wire - Mon Dec 15, 12:00AM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced its collaborator Genentech, a member of the Roche Group, has completed the filing of its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year.
EXEL: 1.29 (-0.01)

Array BioPharma Advances To All Systems Go, Collects $85 Million
Clinically Sound Investor - at Seeking Alpha - Fri Dec 12, 8:13AM CST

ARRY: 4.64 (+0.07), EXEL: 1.29 (-0.01)

Exelixis' COMET-2 Failure And A Discussion Of Potential Future Cash Flow
Daniel Ward - at Seeking Alpha - Wed Dec 03, 2:51PM CST

EXEL: 1.29 (-0.01)

Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:29PM CST
Shares of Exelixis, Inc. (EXEL) dropped 10.2% after the company announced that the trial COMET-2 on cabozantinib did not meet its primary endpoint.
VRX: 140.33 (-0.22), PSTI: 2.46 (unch), EXEL: 1.29 (-0.01)

Is Exelixis, Inc. Stock Doomed?
George Budwell, The Motley Fool - Motley Fool - Tue Dec 02, 7:14AM CST
Biotech stocks are infamous for their volatile ways -- shooting higher one minute, only to crater the next. After a biotech crashes, investors should always assess their options going forward. Sometimes a marked sell-off represents a compelling...
EXEL: 1.29 (-0.01)

Update: Exelixis Announces Final COMET-2 Data- What Can Shareholders Do?
Christopher F. Davis - at Seeking Alpha - Mon Dec 01, 12:31PM CST

EXEL: 1.29 (-0.01)

Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study
at The Street - Mon Dec 01, 10:37AM CST
All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.
EXEL: 1.29 (-0.01)

Exelixis Down 15.1%, Shares Slide into the Red (EXEL)
Comtex SmarTrend(R) - Mon Dec 01, 10:08AM CST
Exelixis (NASDAQ:EXEL) is one of today's worst performing low-priced stocks, down 15.1% to $1.41 on 2.0x average daily volume. Thus far today, Exelixis has traded 3.8 million shares, vs. average volume of 1.9 million shares per day. The stock has underperformed the Dow (-15.1% to the Dow's -0.4%) and underperformed the S&P 500 (-15.1% to the S&P's -0.9%) during today's trading.
EXEL: 1.29 (-0.01)

Exelixis drops 15% after prostate cancer drug candidate fails Phase 3
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 9:14AM CST

EXEL: 1.29 (-0.01)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 8:13AM CST

KOG: 6.56 (-0.39), HK: 1.96 (-0.08), FRO: 2.43 (-0.01), ISR: 1.54 (+0.04), EOX: 1.33 (+0.05), DWA: 22.72 (+0.05), SSE: 6.64 (-0.03), CANF: 3.70 (+0.01), VNET: 15.89 (+0.03), GRPN: 7.89 (-0.14), POZN: 7.86 (+0.07), ONNN: 10.22 (+0.05), EXEL: 1.29 (-0.01)

Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer
Business Wire - Mon Dec 01, 7:01AM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-2, a randomized, double-blind, controlled trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) who are suffering from moderate to severe pain despite optimized narcotic medication, and whose disease has progressed following treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of alleviation of bone pain, as determined by comparing the percentage of patients in the two treatment arms who achieved a pain response at Week 6 that was confirmed at Week 12 without increase in narcotic medication. Fifteen percent of patients in the cabozantinib arm reported a pain response, compared to 17 percent of patients in the control arm receiving mitoxantrone/ prednisone. The difference in pain response between the arms was not statistically significant. The safety profile of cabozantinib in the trial was consistent with that observed in previous studies in mCRPC.
EXEL: 1.29 (-0.01)

Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2
Business Wire - Tue Nov 25, 3:05PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at the Piper Jaffray 26th Annual Healthcare Conference taking place December 2-3 in New York. The Exelixis presentation is scheduled for 1:30 p.m. EST/10:30 a.m. PST on Tuesday, December 2, 2014.
EXEL: 1.29 (-0.01)

Exelixis: Why This Company Could Become The Next Dendreon
Daniel Ward - at Seeking Alpha - Tue Nov 18, 11:54AM CST

EXEL: 1.29 (-0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading